Cytokine Signalling Forum

Publications




Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

López-Romero P, Martinez-Gamboa L, Bang H, de la Torre I, Holzkämper T, Feist E. - Arthritis Res Ther. 2020;22(1):193

Autoantibodies associated with the onset of RA have gained attention in recent years as prognostic biomarkers. Though not used diagnostically, anti-CarbV (carbamylated vimentin) and anti-MCV (vimentin modified by citrullination) baseline titers are being investigated as predictors of treatment response. In this post-hoc analysis of data from the RA-BEGIN cohort of active RA patients, López-Romero and colleagues consider the potential predictive values of baseline anti-CarbV and anti-MCV titers regarding SDAI score improvements and radiographic progression of RA.
The RA-BEGIN cohort considers active RA patients undergoing one of three treatment arms, either receiving MTX or baricitinib monotherapy, or combination therapy. Several endpoints were analysed by multivariable mixed-effect model analysis and multivariable logistic regression models.
Improvement of SDAI scores as an endpoint for treatment response demonstrated a significant association with higher anti-CarbV baseline titers, but not anti-MCV. Patients with higher baseline titers of anti-CarbV autoantibodies were also more likely to demonstrate larger change from baseline to smallest detectable change up to 52 weeks. However, this associated was not statistically significant.
Baseline anti-CarbV and anti-MCV titer values did not demonstrate a statistically significant association to structural damage progression in RA patients. However, further research is necessary to confirm these observations regarding both treatment response and radiographic progression of disease.

Access original article via Pubmed

Upload date: September 2020

Article image